Literature DB >> 28451704

[Benign tumours and tumour-like lesions of the bone : General treatment principles].

H Fritzsche1, K-D Schaser2, C Hofbauer1.   

Abstract

BACKGROUND: Benign bone lesions are much more common than malignant lesions. Some benign bone tumors have a characteristic and typical radiographic appearance, while others are more challenging. Therapy of benign bone tumors differs greatly. While the majority of benign bone tumors do not require surgical therapy, other specific lesions, e. g. aneurysmal bone cysts or giant cell tumors (GCT) of the bone require surgery due to their locally aggressive behavior. DIAGNOSTICS: The major challenge for the radiologist and/or pathologist is the differentiation between a benign and low-grade malignant lesion (e. g. enchondroma versus low-grade chondrosarcoma) for which all available clinical and radiographic information is mandatory. Therefore, surgical therapy is rather more often performed than necessary due to uncertainty in many cases. THERAPY: Novel systemic therapies are available for fibrous dysplasia and GCT of the bone: Fibrous dysplasia can be treated with bisphosphonates, and GCT responds to denosumab. In fact, denosumab has been approved for the treatment of irresectable GCT. Osteoid osteoma is fairly easy to recognize and also to treat given the characteristic clinical presentation and rapid and effective response to local therapy (possible as percutaneous thermo-/laser ablation). In summary, several therapeutic options exist for benign bone tumors, and the choice depends upon the tendency/risk of local recurrence, the rate of surgical complications, options for defect reconstruction, postoperative functional deficits, and specific patient characteristics.

Entities:  

Keywords:  Aneurysmal bone cysts; Benign bone neoplasm; Diagnostic; Enchondroma; Giant Cell Tumors; Neoplasms, bone; Therapy

Mesh:

Year:  2017        PMID: 28451704     DOI: 10.1007/s00132-017-3429-z

Source DB:  PubMed          Journal:  Orthopade        ISSN: 0085-4530            Impact factor:   1.087


  44 in total

1.  Giant cell tumors of the bone: molecular profiling and expression analysis of Ephrin A1 receptor, Claudin 7, CD52, FGFR3 and AMFR.

Authors:  Raphaela Guenther; Veit Krenn; Lars Morawietz; Anja Dankof; Ingo Melcher; Klaus-Dieter Schaser; Hans-Udo Kasper; Ralf-Jürgen Kuban; Ute Ungethüm; Christine Sers
Journal:  Pathol Res Pract       Date:  2005-09-26       Impact factor: 3.250

Review 2.  Metaphyseal and diaphyseal chondroblastomas.

Authors:  Aditya V Maheshwari; James S Jelinek; Albert J Song; Kenneth J Nelson; Mark D Murphey; Robert M Henshaw
Journal:  Skeletal Radiol       Date:  2011-07-20       Impact factor: 2.199

Review 3.  Fibrous dysplasia. Pathophysiology, evaluation, and treatment.

Authors:  Matthew R DiCaprio; William F Enneking
Journal:  J Bone Joint Surg Am       Date:  2005-08       Impact factor: 5.284

4.  Clinical and radiological long-term results after operative treatment of chondroblastoma.

Authors:  Burkhard Lehner; Daniela Witte; Stefan Weiss
Journal:  Arch Orthop Trauma Surg       Date:  2010-04-03       Impact factor: 3.067

5.  Expression of FGF23 is correlated with serum phosphate level in isolated fibrous dysplasia.

Authors:  Keisuke Kobayashi; Yasuo Imanishi; Hiroyuki Koshiyama; Akimitsu Miyauchi; Kenichi Wakasa; Takehisa Kawata; Hitoshi Goto; Hirotsugu Ohashi; Hajime M Koyano; Ryuichi Mochizuki; Takami Miki; Masaaki Inaba; Yoshiki Nishizawa
Journal:  Life Sci       Date:  2005-12-07       Impact factor: 5.037

6.  Chondroblastoma of bone.

Authors:  A J Ramappa; F Y Lee; P Tang; J R Carlson; M C Gebhardt; H J Mankin
Journal:  J Bone Joint Surg Am       Date:  2000-08       Impact factor: 5.284

7.  The natural history of unicameral bone cyst after steroid injection.

Authors:  R Capanna; A Dal Monte; S Gitelis; M Campanacci
Journal:  Clin Orthop Relat Res       Date:  1982-06       Impact factor: 4.176

8.  Radiographic differentiation of enchondroma from low-grade chondrosarcoma in the fibula.

Authors:  Scott D Kendell; Mark S Collins; Mark C Adkins; Murali Sundaram; Krishnan K Unni
Journal:  Skeletal Radiol       Date:  2004-06-23       Impact factor: 2.199

9.  Radiofrequency ablation of chondroblastoma: procedure technique, clinical and MR imaging follow up of four cases.

Authors:  M Christie-Large; N Evans; A M Davies; S L J James
Journal:  Skeletal Radiol       Date:  2008-07-19       Impact factor: 2.199

10.  Radiofrequency ablation of osteoid osteomas: analgesia and patient satisfaction in long-term follow-up.

Authors:  B Gebauer; F Collettini; C Bruger; K-D Schaser; I Melcher; P-U Tunn; F Streitparth
Journal:  Rofo       Date:  2013-08-23
View more
  5 in total

Review 1.  Percutaneous Treatments of Benign Bone Tumors.

Authors:  Guillaume Koch; Roberto Luigi Cazzato; Andrew Gilkison; Jean Caudrelier; Julien Garnon; Afshin Gangi
Journal:  Semin Intervent Radiol       Date:  2018-11-05       Impact factor: 1.513

2.  The minimally invasive endoscopic technique for the treatment of symptomatic benign bone lesions: Preliminary results from a retrospective study.

Authors:  Min-Hao Wu; Ling-Fei Xiao; Chong Zhang; Jun Lei; Zhou-Ming Deng
Journal:  J Bone Oncol       Date:  2020-08-02       Impact factor: 4.072

3.  Using Machine Learning to Unravel the Value of Radiographic Features for the Classification of Bone Tumors.

Authors:  Derun Pan; Renyi Liu; Bowen Zheng; Jianxiang Yuan; Hui Zeng; Zilong He; Zhendong Luo; Genggeng Qin; Weiguo Chen
Journal:  Biomed Res Int       Date:  2021-03-11       Impact factor: 3.411

4.  Using a combination of gangliosides and cell surface vimentin as surface biomarkers for isolating osteosarcoma cells in microfluidic devices.

Authors:  Henrietta O Fasanya; Pablo J Dopico; Zachary Yeager; Z Hugh Fan; Dietmar W Siemann
Journal:  J Bone Oncol       Date:  2021-03-24       Impact factor: 4.491

5.  Edema Surrounding Benign Tumors and Tumor-Like Lesions.

Authors:  Sai Gao; Ruizhi Zhou; Qi Xu; Haisong Chen
Journal:  Biomed Res Int       Date:  2019-10-29       Impact factor: 3.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.